Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 158

Results For "NAL"

6619 News Found

STEER World achieves 200 kg/hr continuous granulation with patented INTEGRAAL system
News | August 17, 2025

STEER World achieves 200 kg/hr continuous granulation with patented INTEGRAAL system

The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules


Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
News | August 17, 2025

Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr

Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent


Firstsource and Guidehealth partner to advance AI-enabled value-based care for health plans
Healthcare | August 17, 2025

Firstsource and Guidehealth partner to advance AI-enabled value-based care for health plans

The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation


UFlex posts Q1 FY26 PAT at Rs. 58 Cr
News | August 17, 2025

UFlex posts Q1 FY26 PAT at Rs. 58 Cr

The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization


Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
News | August 17, 2025

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase


Cohance Lifesciences reports 13% revenue growth in Q1 FY26
News | August 16, 2025

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site


AAVantgarde Bio receives FDA fast track designation for AAVB-039 in stargardt disease
Biotech | August 16, 2025

AAVantgarde Bio receives FDA fast track designation for AAVB-039 in stargardt disease

The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations


Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
News | August 13, 2025

Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent


Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
News | August 13, 2025

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY